Roberto B Cattaneo

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics
    G Ungerechts
    Department of Molecular Medicine and Virology and Gene Therapy Track, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Gene Ther 17:1506-16. 2010
  2. pmc The heads of the measles virus attachment protein move to transmit the fusion-triggering signal
    Chanakha K Navaratnarajah
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Nat Struct Mol Biol 18:128-34. 2011
  3. pmc Development of measles virus-based shielded oncolytic vectors: suitability of other paramyxovirus glycoproteins
    A W Hudacek
    Department of Molecular Medicine, Virology and Gene Therapy Track, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Gene Ther 20:109-16. 2013
  4. pmc Four viruses, two bacteria, and one receptor: membrane cofactor protein (CD46) as pathogens' magnet
    Roberto Cattaneo
    Molecular Medicine Program, Mayo Clinic, and Virology and Gene Therapy, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Virol 78:4385-8. 2004
  5. pmc A ferret model of canine distemper virus virulence and immunosuppression
    Veronika von Messling
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Virol 77:12579-91. 2003
  6. pmc Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
    Roberto Cattaneo
    Department of Molecular Medicine, Rochester, MayoClinic, Minnesota 55905, USA
    Nat Rev Microbiol 6:529-40. 2008
  7. ncbi request reprint Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression
    Deanna Grote
    Molecular Medicine Program, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Res 63:6463-8. 2003
  8. ncbi request reprint Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter
    David Dingli
    Molecular Medicine Program, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Blood 103:1641-6. 2004
  9. ncbi request reprint Antibody-targeted cell fusion
    Takafumi Nakamura
    Molecular Medicine Program, Mayo Foundation, 200 First St SW, Rochester, Minnesota 55905, USA
    Nat Biotechnol 22:331-6. 2004
  10. pmc Tropism illuminated: lymphocyte-based pathways blazed by lethal morbillivirus through the host immune system
    Veronika von Messling
    Molecular Medicine Program and Virology and Gene Therapy Graduate Track, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Proc Natl Acad Sci U S A 101:14216-21. 2004

Research Grants

Collaborators

Detail Information

Publications42

  1. pmc Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics
    G Ungerechts
    Department of Molecular Medicine and Virology and Gene Therapy Track, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Gene Ther 17:1506-16. 2010
    ..These studies document a reprogrammed oncolytic virus, consolidating the effects of two chemotherapeutics, a concept well suited for a phase I clinical trial for MCL patients for whom conventional therapies have failed...
  2. pmc The heads of the measles virus attachment protein move to transmit the fusion-triggering signal
    Chanakha K Navaratnarajah
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Nat Struct Mol Biol 18:128-34. 2011
    ..We discuss how receptors may force H-protein heads to switch partners and transmit the fusion-triggering signal...
  3. pmc Development of measles virus-based shielded oncolytic vectors: suitability of other paramyxovirus glycoproteins
    A W Hudacek
    Department of Molecular Medicine, Virology and Gene Therapy Track, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Gene Ther 20:109-16. 2013
    ..Ultimately, this interferes with applications for oncolytic virotherapy. Alternative strategies for the generation of shielded MV are discussed...
  4. pmc Four viruses, two bacteria, and one receptor: membrane cofactor protein (CD46) as pathogens' magnet
    Roberto Cattaneo
    Molecular Medicine Program, Mayo Clinic, and Virology and Gene Therapy, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Virol 78:4385-8. 2004
  5. pmc A ferret model of canine distemper virus virulence and immunosuppression
    Veronika von Messling
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Virol 77:12579-91. 2003
    ..Thus, virulence-inducing mutations have accumulated throughout the genome...
  6. pmc Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
    Roberto Cattaneo
    Department of Molecular Medicine, Rochester, MayoClinic, Minnesota 55905, USA
    Nat Rev Microbiol 6:529-40. 2008
    ..Virus-based therapeutics are beginning to find their place in cancer clinical practice, in combination with chemotherapy and radiation...
  7. ncbi request reprint Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression
    Deanna Grote
    Molecular Medicine Program, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Res 63:6463-8. 2003
    ..The magnitude of the neutrophil response correlated well with tumor regression. Our studies suggest that therapy with replicating MV stimulates a strong neutrophil antitumor response, which can be cytokine-enhanced to improve oncolysis...
  8. ncbi request reprint Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter
    David Dingli
    Molecular Medicine Program, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Blood 103:1641-6. 2004
    ..Testing in other radiosensitive cancers is warranted...
  9. ncbi request reprint Antibody-targeted cell fusion
    Takafumi Nakamura
    Molecular Medicine Program, Mayo Foundation, 200 First St SW, Rochester, Minnesota 55905, USA
    Nat Biotechnol 22:331-6. 2004
    ....
  10. pmc Tropism illuminated: lymphocyte-based pathways blazed by lethal morbillivirus through the host immune system
    Veronika von Messling
    Molecular Medicine Program and Virology and Gene Therapy Graduate Track, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Proc Natl Acad Sci U S A 101:14216-21. 2004
    ..Thus, CDV initially infects lymphocytes and massively replicates therein, thereby causing immunosuppression and preparing systemic invasion and host escape...
  11. pmc Efficiency of measles virus entry and dissemination through different receptors
    Urs Schneider
    Molecular Medicine Program, Mayo Foundation, Rochester, Minnesota 55905, USA
    J Virol 76:7460-7. 2002
    ..To verify the importance of these observations for human infections, we examined MV entry into peripheral blood mononuclear cells and observed that viruses with asparagine 481 H proteins infect these cells more efficiently...
  12. pmc Nearby clusters of hemagglutinin residues sustain SLAM-dependent canine distemper virus entry in peripheral blood mononuclear cells
    Veronika von Messling
    Molecular Medicine Program, Mayo Clinic, Guggenheim 1838, 200 1st Street SW, Rochester, MN 55905, USA
    J Virol 79:5857-62. 2005
    ..We rescued a SLAM-blind recombinant CDV with six mutations that did not infect ferret peripheral blood mononuclear cells while retaining full infectivity in epithelial cells...
  13. pmc Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model
    Sompong Vongpunsawad
    Molecular Medicine Program, Mayo Clinic, and Virology and Gene Therapy, Mayo Graduate School, Rochester, Minnesota 55095, USA
    J Virol 78:302-13. 2004
    ..Selectively receptor-blind viruses will be used to study MV pathogenesis and may have applications for the production of novel vaccines and therapeutics...
  14. pmc Engineered measles virus as a novel oncolytic therapy against prostate cancer
    Pavlos Msaouel
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Prostate 69:82-91. 2009
    ..In this study, we investigated the antitumor potential of recombinant MV-Edm derivatives as novel oncolytic agents against prostate cancer...
  15. pmc Dynamic interaction of the measles virus hemagglutinin with its receptor signaling lymphocytic activation molecule (SLAM, CD150)
    Chanakha K Navaratnarajah
    Department of Molecular Medicine and Virology and Gene Therapy Graduate Track, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Biol Chem 283:11763-71. 2008
    ..Our study sets a structure-based stage for understanding how the SLAM-elicited conformational changes travel through the H-protein ectodomain before triggering fusion protein unfolding and membrane fusion...
  16. ncbi request reprint An immunocompetent murine model for oncolysis with an armed and targeted measles virus
    Guy Ungerechts
    Molecular Medicine Program and Virology and Gene Therapy Track, Mayo Clinic College of Medicine, Rochester, Minnesota 55902, USA
    Mol Ther 15:1991-7. 2007
    ..This immunocompetent murine model facilitates the testing of therapeutic regimens for clinical trials...
  17. pmc Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed
    Vincent H J Leonard
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    J Clin Invest 118:2448-58. 2008
    ..Thus, EpR is probably a basolateral protein, and infection of the airway epithelium is not essential for systemic spread and virulence of MV...
  18. ncbi request reprint Interaction of measles virus vectors with Auger electron emitting radioisotopes
    David Dingli
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Biochem Biophys Res Commun 337:22-9. 2005
    ..MV-NICE does not replicate faster in the presence of radiation. Auger electron emitting isotopes effectively stop propagation of MV vectors expressing NIS in vitro. Additional work is necessary to translate these observations in vivo...
  19. pmc A recombinant measles virus unable to antagonize STAT1 function cannot control inflammation and is attenuated in rhesus monkeys
    Patricia Devaux
    Department of Molecular Medicine, Mayo Clinic and Foundation, Guggenheim 18 01B, 200 First Street SW, Rochester, MN 55905, USA
    J Virol 85:348-56. 2011
    ..They also suggest that selectively STAT1-blind MV may have utility as vectors for targeted oncolysis and vaccination...
  20. ncbi request reprint Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker
    Kah Whye Peng
    Molecular Medicine Program, Mayo Foundation, Rochester, MN 55905, USA
    Blood 101:2557-62. 2003
    ..Tumorigenicity of CHO-CD38 cells in immunocompromised mice was significantly attenuated by MV-alpha CD38, resulting in enhanced survival of these mice compared with the control group...
  21. ncbi request reprint Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice
    Kah Whye Peng
    Molecular Medicine Program, Guggenheim 18, Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Hum Gene Ther 14:1565-77. 2003
    ....
  22. ncbi request reprint Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity
    Cory Allen
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 66:11840-50. 2006
    ....
  23. ncbi request reprint An oncolytic measles virus engineered to enter cells through the CD20 antigen
    Amanda D Bucheit
    Mayo Clinic Molecular Medicine Program, 200 First Street SW, Rochester, Minnesota 55902, USA
    Mol Ther 7:62-72. 2003
    ....
  24. pmc Measles virus infection of alveolar macrophages and dendritic cells precedes spread to lymphatic organs in transgenic mice expressing human signaling lymphocytic activation molecule (SLAM, CD150)
    Claudia S Antunes Ferreira
    Department of Molecular Medicine, and Virology and Gene Therapy Track, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Virol 84:3033-42. 2010
    ..Thus, MV infection of alveolar macrophages and subepithelial dendritic cells in the airways precedes infection of lymphocytes in lymphatic organs of mice expressing human SLAM with human-like tissue specificity...
  25. pmc Measles virus phosphoprotein gene products: conformational flexibility of the P/V protein amino-terminal domain and C protein infectivity factor function
    Patricia Devaux
    Molecular Medicine Program and Virology and Gene Therapy Graduate Track, Mayo Clinic College, Rochester, MN, USA
    J Virol 78:11632-40. 2004
    ..Intracellular titers of this virus were almost completely restored, and those of released virus were partially restored. Thus, the MV C protein is an infectivity factor...
  26. pmc The measles virus fusion protein transmembrane region modulates availability of an active glycoprotein complex and fusion efficiency
    Michael D Mühlebach
    Mayo Clinic, Department of Molecular Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Virol 82:11437-45. 2008
    ..Thus, fusion activity correlated with an active F-H protein complex, and the MV F protein TM region modulated availability of this complex...
  27. ncbi request reprint Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine
    Guy Ungerechts
    Molecular Medicine Program and Virology and Gene Therapy Track, Mayo Clinic College of Medicine, Rochester, Minnesota 55902, USA
    Cancer Res 67:10939-47. 2007
    ..Cells from MCL patients were shown to be sensitive to infection. Thus, synergy of F-araAMP with a PNP-armed and CD20-targeted MV was shown in one lymphoma therapy model after systemic vector inoculation...
  28. pmc Polyploid measles virus with hexameric genome length
    Monika Rager
    Molecular Medicine Program, Mayo Clinic, Guggenheim 1838, 200 First Street SW, Rochester, MN 55905, USA
    EMBO J 21:2364-72. 2002
    ..Our results illustrate how the particles of parainfluenza viruses efficiently accommodate cargoes of different volume, and suggest a mechanism by which segmented genomes may have evolved...
  29. pmc Strength of envelope protein interaction modulates cytopathicity of measles virus
    Richard K Plemper
    Molecular Medicine Program, Mayo Foundation, Rochester, Minnesota 55905, USA
    J Virol 76:5051-61. 2002
    ..Similar analyses of glycoproteins derived from MV strains with reduced cytopathicities confirm that the strength of H and F glycoprotein interaction is a modulator of viral fusogenicity...
  30. ncbi request reprint Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases
    Christoph Springfeld
    Molecular Medicine Program and Virology and Gene Therapy Track, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55902, USA
    Cancer Res 66:7694-700. 2006
    ..This study opens the perspective of combining targeting at the particle activation, receptor recognition, and selective replication levels to improve the therapeutic index of MV and other viruses in ongoing clinical trials of oncolysis...
  31. pmc Canine distemper virus and measles virus fusion glycoprotein trimers: partial membrane-proximal ectodomain cleavage enhances function
    Veronika von Messling
    Molecular Medicine Program, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA
    J Virol 78:7894-903. 2004
    ..We envisage that selective loss of the membrane anchor in the external subunits of circularly arranged F protein trimers may disengage them from pulling the membrane centrifugally, thereby facilitating fusion pore formation...
  32. pmc N-linked glycans with similar location in the fusion protein head modulate paramyxovirus fusion
    Veronika von Messling
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Virol 77:10202-12. 2003
    ..Thus, structural information about the F proteins of Paramyxoviridae coupled with functional analysis disclosed a location in the protein head into which fusion-modulating glycans independently evolved...
  33. pmc Amino-terminal precursor sequence modulates canine distemper virus fusion protein function
    Veronika von Messling
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Virol 76:4172-80. 2002
    ..Thus, the Pre peptide modulates the function of the CDV F protein. Interestingly, a distinct two-hit activation process has been recently described for human respiratory syncytial virus, another paramyxovirus...
  34. ncbi request reprint Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation
    Patricia Devaux
    Molecular Medicine Program and Virology and Gene Therapy Graduate Track, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Virology 360:72-83. 2007
    ..Our study also identifies a conserved sequence around P protein tyrosine 110 as a candidate interaction site with a cellular protein...
  35. pmc Envelope targeting: hemagglutinin attachment specificity rather than fusion protein cleavage-activation restricts Tupaia paramyxovirus tropism
    Christoph Springfeld
    Mayo Clinic Rochester, Molecular Medicine Program, Guggenheim 1838, 200 First St SW, Rochester, MN 55902, USA
    J Virol 79:10155-63. 2005
    ..Targeting competence and the absence of antibodies in humans define the TPMV envelope as a module to be adapted for ferrying ribonucleocapsids of oncolytic viruses and gene delivery vectors...
  36. pmc Attenuation of V- or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys
    Patricia Devaux
    Department of Molecular Medicine and Virology and Gene Therapy Graduate Track, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Virol 82:5359-67. 2008
    ..Moreover, MV unable to interact with single innate immunity proteins may be developed for preferential replication in tumors with specific contexts of vulnerability...
  37. pmc Receptor (SLAM [CD150]) recognition and the V protein sustain swift lymphocyte-based invasion of mucosal tissue and lymphatic organs by a morbillivirus
    Veronika von Messling
    Mayo Clinic College of Medicine, Rochester, MN 55902, USA
    J Virol 80:6084-92. 2006
    ..They also reveal how two viral proteins affect pathogenesis: V sustains the swift lymphocyte-based invasion of mucosal tissue and lymphatic organs, whereas C sustains subsequent infection phases...
  38. pmc A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge
    Jorge Reyes del Valle
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Virol 81:10597-605. 2007
    ..This threshold is lower in mice than in macaques. Implications for the development of divalent vaccines based on live attenuated viruses are discussed...
  39. pmc Measles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys
    Vincent H J Leonard
    Mayo Clinic, Department of Molecular Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Virol 84:3413-20. 2010
    ..These findings prove formally that efficient SLAM recognition is necessary for MV virulence and pathogenesis. They also suggest that the selectively SLAM-blind wild-type MV can be developed into a vaccine vector...
  40. pmc Protective anti-hepatitis B virus responses in rhesus monkeys primed with a vectored measles virus and boosted with a single dose of hepatitis B surface antigen
    Jorge Reyes-Del Valle
    Department of Molecular Medicine and Virology and Gene Therapy Graduate Track, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Virol 83:9013-7. 2009
    ..Vaccination strategies coupling the effective, long-term immunity elicited by the high-coverage MV vaccine to prophylactic HBV immunity are discussed...
  41. pmc Characterization of the Tupaia rhabdovirus genome reveals a long open reading frame overlapping with P and a novel gene encoding a small hydrophobic protein
    Christoph Springfeld
    Mayo Clinic Rochester, Molecular Medicine Program, Guggenheim 1838, 200 First Street SW, Rochester, MN 55902, USA
    J Virol 79:6781-90. 2005
    ....

Research Grants19

  1. Measles Virus Entry
    Roberto Cattaneo; Fiscal Year: 2005
    ..abstract_text> ..
  2. Measles Viruses with Added Vaccine Specificities
    Roberto Cattaneo; Fiscal Year: 2007
    ..Their efficacy in protecting these primates against wild type measles infection and in inducing an immune response against the additional pathogen will be measured. ..
  3. Measles Virus Entry: Engagement of the Receptors and Infection Progression
    Roberto Cattaneo; Fiscal Year: 2009
    ..It will also boost further development of oncolytic viruses, targeted. ..
  4. Measles Virus Entry: Engagement of the Receptors and Infection Progression
    Roberto B Cattaneo; Fiscal Year: 2010
    ..It will also boost further development of oncolytic viruses, targeted. ..
  5. Lymphoma Therapy with Reprogrammed Measles Viruses
    Roberto B Cattaneo; Fiscal Year: 2010
    ....
  6. Measles Viruses with Added Vaccine Specificities
    Roberto Cattaneo; Fiscal Year: 2006
    ..Their efficacy in protecting these primates against wild type measles infection and in inducing an immune response against the additional pathogen will be measured. ..
  7. Immunosuppresion by Measles & Canine Distemper Viruses
    Roberto Cattaneo; Fiscal Year: 2005
    ..abstract_text> ..
  8. Lymphoma Therapy with Reprogrammed Measles Viruses
    Roberto B Cattaneo; Fiscal Year: 2011
    ....
  9. Measles Virus Entry: Engagement of the Receptors and Infection Progression
    Roberto Cattaneo; Fiscal Year: 2007
    ..It will also boost further development of oncolytic viruses, targeted. ..
  10. Immunosuppresion by Measles & Canine Distemper Viruses
    Roberto Cattaneo; Fiscal Year: 2007
    ..abstract_text> ..
  11. Measles Virus Entry
    Roberto Cattaneo; Fiscal Year: 2002
    ..abstract_text> ..
  12. Immunosuppresion by Measles & Canine Distemper Viruses
    Roberto Cattaneo; Fiscal Year: 2006
    ..abstract_text> ..
  13. Measles Viruses with Added Vaccine Specificities
    Roberto Cattaneo; Fiscal Year: 2005
    ..Their efficacy in protecting these primates against wild type measles infection and in inducing an immune response against the additional pathogen will be measured. ..
  14. Measles Virus Entry
    Roberto Cattaneo; Fiscal Year: 2004
    ..abstract_text> ..
  15. Measles Viruses with Added Vaccine Specificities
    Roberto Cattaneo; Fiscal Year: 2004
    ..Their efficacy in protecting these primates against wild type measles infection and in inducing an immune response against the additional pathogen will be measured. ..
  16. Measles Virus Entry
    Roberto Cattaneo; Fiscal Year: 2003
    ..abstract_text> ..
  17. Immunosuppression and Innate Immunity Control by Morbilliviruses
    Roberto B Cattaneo; Fiscal Year: 2010
    ..The results of this research will provide solid foundations for developing measles virus-based multivalent vaccines and cancer therapeutics. ..